Guardion Health Sciences (NASDAQ:GHSI – Get Free Report) and Schrödinger (NASDAQ:SDGR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Earnings & Valuation
This table compares Guardion Health Sciences and Schrödinger’s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Guardion Health Sciences | $12.25 million | 1.03 | $160,000.00 | ($4.02) | -2.46 |
Schrödinger | $216.67 million | 7.51 | $40.72 million | ($1.88) | -11.91 |
Schrödinger has higher revenue and earnings than Guardion Health Sciences. Schrödinger is trading at a lower price-to-earnings ratio than Guardion Health Sciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
Profitability
This table compares Guardion Health Sciences and Schrödinger’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Guardion Health Sciences | -16.69% | -77.29% | -42.08% |
Schrödinger | -75.94% | -29.25% | -20.60% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Guardion Health Sciences and Schrödinger, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Guardion Health Sciences | 0 | 1 | 0 | 0 | 2.00 |
Schrödinger | 0 | 3 | 7 | 1 | 2.82 |
Schrödinger has a consensus price target of $38.90, indicating a potential upside of 73.66%. Given Schrödinger’s stronger consensus rating and higher possible upside, analysts clearly believe Schrödinger is more favorable than Guardion Health Sciences.
Risk and Volatility
Guardion Health Sciences has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
Summary
Schrödinger beats Guardion Health Sciences on 13 of the 15 factors compared between the two stocks.
About Guardion Health Sciences
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
About Schrödinger
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Receive News & Ratings for Guardion Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardion Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.